Study of PXL065 in Patients With Nonalcoholic Steatohepatitis (NASH)

PHASE2CompletedINTERVENTIONAL
Enrollment

117

Participants

Timeline

Start Date

September 1, 2020

Primary Completion Date

June 8, 2022

Study Completion Date

June 20, 2022

Conditions
NASH - Nonalcoholic Steatohepatitis
Interventions
DRUG

PXL065

PXL065 oral tablet

DRUG

Placebo oral tablet

Placebo oral tablet

Trial Locations (29)

13057

Study site 27, East Syracuse

28304

Study site 14, Fayetteville

29485

Study site 29, Summerville

32127

Study site 08, Port Orange

33434

Study site 15, Boca Raton

33912

Study site 31, Fort Myers

34240

Study site 01, Sarasota

37040

Study site 30, Clarksville

37411

Study site 25, Chattanooga

38138

Study Site 02, Germantown

39216

Study site 10, Jackson

39232

Study site 24, Flowood

50265

Study site 28, West Des Moines

61431

Study site 18, Kansas City

78229

Pinnacle Clinical Research (Study site 20), San Antonio

78539

Study site 09, Edinburg

Study site 23, Edinburg

78746

Study site 19, Austin

85224

Study site 11, Chandler

85306

Study site 12, Glendale

85712

Study site 13, Tucson

Study site 21, Tucson

90057

Study site 05, Los Angeles

90255

Study site 04, Huntington Park

90402

Study site 06, Panorama City

91910

Study site 17, Chula Vista

92704

Study site 07, Santa Ana

92866

Study site 22, Orange

93720

Study site 16, Fresno

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Poxel SA

INDUSTRY